Nuvama sees 15% upside in this pharma stock: 3 reasons revealed
Nuvama Institutional Equities maintains 'Buy' call on Divi's Laboratories with a target price of Rs 7,110, citing the company's partnership with Eli Lilly and the potential launch of its oral GLP-1 drug, Orforglipron. Nuvama believes this drug has the potential to benefit a large global population and could generate peak sales of $15-40 billion.